

lxxxiv. 1-benzyl-4-(R)-benzyl-2,5-imidazolidinedione-N-[1-(2-(5-(3-methylbenzyl)-1,3,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]acetamide;

lxxxv. 1-benzyl-4-(R)-benzyl-2,5-imidazolidinedione-N-[1-(3-(5-(3-trifluoromethylbenzyl)-1,2,4-oxadiazolyl)carbonyl)-2-(S)-methylpropyl]acetamide;
pharmaceutically acceptable salts thereof;

or combinations thereof.

Please add the following new claims:

29. (New) The method of Claim 1 wherein said wasting disease includes neurodegenerative disease, myocardial infarction, and stroke.

30 (New) The method of Claim 1 wherein the serine protease inhibitor inhibits at least one of trypsin, cathepsin G, tryptase TL-2, factor Xa, elastase, or proteinase-3.

REMARKS

Claims 1-10 and 12-28 were pending in the application. Claims 26-28 are hereby cancelled without prejudice to pursuing the cancelled claims in this or other continuing applications. Claims 1, 3, 4, 8, 9, 12, 14, 16, 18, 19, 24, and 25 have been amended. New Claims 29 and 30 have been added. Upon entry of these amendments, Claims 1-10, 12-20, 23-25, and 29-30 will be pending and under active consideration. Claims 1, 18, 19, and 25 are independent.